Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
Cloud Subscription Annual Recurring Revenue (ARR) in the fourth quarter and full-year 2023 increased 37% year-over-year…
. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 comb…
Substantially improved survival and progression-free survival under NOX-A12 treatment combination compared to matched st…
Subscription Annual Recurring Revenue (ARR) in the third quarter increased 15% year-over-year to $1.08 billion Cloud Su…
- Allen sechs Patienten der ersten Kohorte (Kohorte A) wurde erfolgreich ein 8-Kanal-Cell-Pouch-System implantiert; d…